DE60120917D1 - Kombinationspräparat zur krebstherapie - Google Patents

Kombinationspräparat zur krebstherapie

Info

Publication number
DE60120917D1
DE60120917D1 DE60120917T DE60120917T DE60120917D1 DE 60120917 D1 DE60120917 D1 DE 60120917D1 DE 60120917 T DE60120917 T DE 60120917T DE 60120917 T DE60120917 T DE 60120917T DE 60120917 D1 DE60120917 D1 DE 60120917D1
Authority
DE
Germany
Prior art keywords
cancer therapy
combination preparation
irinotecan
temozolomide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60120917T
Other languages
English (en)
Other versions
DE60120917T2 (de
Inventor
J Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60120917D1 publication Critical patent/DE60120917D1/de
Application granted granted Critical
Publication of DE60120917T2 publication Critical patent/DE60120917T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60120917T 2000-01-26 2001-01-24 Kombinationspräparat zur krebstherapie Expired - Fee Related DE60120917T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17854100P 2000-01-26 2000-01-26
US178541P 2000-01-26
PCT/US2001/002372 WO2001054678A2 (en) 2000-01-26 2001-01-24 Combination therapy for cancer

Publications (2)

Publication Number Publication Date
DE60120917D1 true DE60120917D1 (de) 2006-08-03
DE60120917T2 DE60120917T2 (de) 2007-01-25

Family

ID=22652952

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120917T Expired - Fee Related DE60120917T2 (de) 2000-01-26 2001-01-24 Kombinationspräparat zur krebstherapie

Country Status (13)

Country Link
US (1) US20030229112A1 (de)
EP (1) EP1251850B1 (de)
JP (1) JP2003521497A (de)
AT (1) ATE330600T1 (de)
AU (1) AU2001236529A1 (de)
CA (1) CA2397523A1 (de)
CY (1) CY1105564T1 (de)
DE (1) DE60120917T2 (de)
DK (1) DK1251850T3 (de)
ES (1) ES2263591T3 (de)
MX (1) MXPA02007242A (de)
PT (1) PT1251850E (de)
WO (1) WO2001054678A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002328945A1 (en) * 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Methods for improved treatment of cancer with irinotecan based on mrp1
EA014157B1 (ru) 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)
AU2007301686B2 (en) * 2006-09-29 2013-02-14 Cipla Limited An improved process for the preparation of temozolomide and analogs
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN112263579A (zh) * 2020-11-10 2021-01-26 天津键凯科技有限公司 一种抗肿瘤药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6955396A (en) * 1995-08-28 1997-03-19 Schering Corporation Combination therapy for advanced cancer comprising temozolomide and cisplatin
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide

Also Published As

Publication number Publication date
MXPA02007242A (es) 2002-12-09
CY1105564T1 (el) 2010-07-28
US20030229112A1 (en) 2003-12-11
CA2397523A1 (en) 2001-08-02
ES2263591T3 (es) 2006-12-16
DK1251850T3 (da) 2006-10-23
WO2001054678A2 (en) 2001-08-02
WO2001054678A3 (en) 2002-01-17
AU2001236529A1 (en) 2001-08-07
EP1251850A2 (de) 2002-10-30
JP2003521497A (ja) 2003-07-15
ATE330600T1 (de) 2006-07-15
PT1251850E (pt) 2006-10-31
EP1251850B1 (de) 2006-06-21
DE60120917T2 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
CY1105564T1 (el) Θεραπεια συνδυασμου για καρκινο
IL182352A0 (en) The use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743
NO20032027L (no) Effektive antitumorbehandlinger
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
GB0020504D0 (en) Therapeutic method
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
MXPA05010804A (es) Torio 227 para uso en radioterapia de enfermedades del tejido blando.
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
TW200517119A (en) Method of treatment using interferon-tau
IL159770A0 (en) Calcium salts with cytotoxic activity
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
PT1150981E (pt) Composto nucleosidico terapeutico
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
NO20043774L (no) The use of devazenide as analgesic agent
BRPI0407301A (pt) Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano
UA30257A (uk) Спосіб нормалізації тканинного обміну та відновлення морфофункціонального стану органів і тканин
UA23985A (uk) Спосіб лікуваhhя запальhих захворюваhь вhутрішhіх геhіталій у дівчат та підлітків
WO2007098183A3 (en) Treatment of cancer with 2-deoxygalactose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee